PathoQuest is a biotech company developing NGS-based metagenomic tests for exhaustive identification of pathogens.
PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 9, 2021 | Series B | €15M | 1 | — | — | Detail |
Sep 6, 2019 | Series Unknown | €8M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Verve Ventures | — | Series B |